Healthcare (SH:603313)2017-04-28 16:00Financial Performance - Operating revenue for the period reached CNY 481,467,924.05, representing a 30.20% increase year-on-year[6] - Net profit attributable to shareholders was CNY 67,354,852.37, up 31.15% from the same period last year[6] - Basic earnings per share were CNY 0.28, a decrease of 3.45% compared to the previous year[6] - Total revenue for the first quarter reached RMB 481,467,924.05, an increase of 30.2% compared to RMB 369,787,054.11 in the same period last year[23] - Operating profit for the first quarter was RMB 65,229,787.84, slightly down from RMB 65,425,335.75 year-on-year[23] - The company reported a comprehensive income of RMB 64,212,377.02, an increase from RMB 50,612,038.16 year-on-year[24] - The net profit for Q1 2017 was CNY 64,388,667.48, an increase of 22.6% compared to CNY 52,508,271.16 in the previous period[26] - The company reported a total profit of CNY 76,300,561.47, which is an increase of 16.8% from CNY 65,622,028.00 in the previous period[26] Assets and Liabilities - Total assets increased by 11.64% to CNY 2,219,778,003.71 compared to the end of the previous year[6] - Total assets reached ¥2,219,778,003.71, up from ¥1,988,290,494.04[16] - Total liabilities increased to ¥489,179,880.56 from ¥322,945,662.46, reflecting a rise in short-term borrowings[17] - Total liabilities rose to RMB 301,828,602.55, compared to RMB 162,787,684.98, indicating an increase of 85.5%[21] Cash Flow - Net cash flow from operating activities decreased by 44.64% to CNY 23,831,440.56 compared to the previous year[6] - Cash and cash equivalents increased by 64.46% to ¥990,338,913.77, primarily due to the maturity of financial products[12] - Cash flow from operating activities net amount was $6,197,861.68, a decrease of 83.6% compared to $37,684,517.46 in the previous year[34] - The net increase in cash and cash equivalents was $374,950,693.22, compared to a decrease of $4,282,216.18 in the same period last year[34] - Cash paid for taxes was $13,097,232.74, an increase of 25.6% compared to $10,465,348.87 in the previous year[34] Shareholder Information - The number of shareholders at the end of the reporting period was 33,231[10] - The largest shareholder, 倪张根, holds 59.02% of the shares, with 141,641,980 shares pledged[10] Government Support and Investments - The company received government subsidies amounting to CNY 15,375,059.20, which are closely related to its normal business operations[6] - Investment income surged by 203.20% to ¥1,499,508.20, resulting from higher financial product returns[12] - Net cash flow from investing activities increased by 891.83% to ¥241,833,345.55, mainly from the recovery of financial products[12] - Cash received from investment income was $1,499,508.20, with no comparable figure from the previous year[34] Operational Insights - Operating costs increased by 40.77% to ¥324,206,761.67, mainly due to rising chemical material costs[12] - The company has not disclosed any new product or technology developments, market expansion, or mergers and acquisitions in this report[11] - The company plans to continue expanding its market presence and invest in new product development to drive future growth[23]